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 Type 2 diabetes is an heterogeneous disease resulting from a dynamic interaction between 
defects in insulin secretion and insulin action.  As most subjects are overweight or obese, the initial 
treatment is optimization of the meal plan and enhancement of physical activity in order to obtain 
sustained weight reduction. In case of failure of life-style changes, various oral antihyperglycaemic 
agents may be used. Some are targeting defective insulin secretion (sulphonylureas, glinides) while 




include both patient’s characteristics (body weight, age, degree of hyperglycaemia, age, comorbidities) 
and pharmacological properties of the compound (mode of action, safety profile, cost). Monotherapy is 
usually recommended first, but combined therapy using drugs with additive or synergistic effects may 
be required to obtain appropriate blood glucose control. As the natural history of the disease is 
characterized by a progressive exhaustion of beta-cells, exogenous insulin may be required in the long 
term, usually in combination with oral agents. Finally, as patients with type 2 diabetes are insulin-
resistant and often have a metabolic syndrome, a multifactorial intervention including aggressive 
treatment of arterial hypertension and dyslipidaemia is recommended in order to reduce the incidence 
of cardiovascular complications. 
 






 Type 2 diabetes mellitus is one of the leading cause of death by disease in the western world 
and also contributes to higher rates of severe morbidity as people with diabetes are at higher risk for 
heart disease, blindness, kidney failure, extremity amputations, and other chronic conditions. 
Eliminating or reducing the health problems caused by diabetes through factors such as better access to 
preventive care, more widespread diagnosis and more intensive disease management could significantly 
improve the quality of life for diabetic individuals and their families while at the same time potentially 
reducing the enormous cost burden to society (1). 
 Type 2 diabetes is an heterogeneous condition caused by both genetic and environmental 
factors. Hyperglycaemia results from a dynamic interaction between defects in insulin secretion and 
insulin action (2). It is characterized by a progressive deterioration of the metabolic status over years 
that essentially results from a progressive decline of insulin secretion by pancreatic islet beta-cells. 
Therefore, the management of the disease usually requires a stepwise adjustment of pharmacological 
therapies in combination with life-style modifications, which ultimately may lead to insulin 
requirement  (3). Such a strategy includes a progressive increase in the daily dosages of each molecule 
used and/or appropriate combinations of various glucose-lowering agents with complementary and, 
ideally, synergistic modes of action (4,5). 
 Most patients with type 2 diabetes are obese or have an increased percentage of body fat 
distributed predominantly in the intra-abdominal (peri-visceral) region (6). Besides hyperglycaemia, 
other abnormalities are frequently present and most probably related to visceral adiposity : 
dyslipidaemias (hypertriglyceridaemia, low HDL cholesterol, increased small dense LDL particles, 
postprandial hyperlipaemia, ...), arterial hypertension (in about half of overweight patients with type 2 
diabetes), fibrinolytic disturbances (increased plasminogen-activator inhibitor-1 or PAI-1 levels) and 
increased inflammation markers (C-reactive protein, fibrinogen). All these abnormalities are well-
documented cardiovascular risk factors. They are related to insulin resistance (syndrome X or 
metabolic syndrome) and may be present even in absence of severe hyperglycaemia (7). Consequently, 
therapeutic guidelines of type 2 diabetes should not focus only on the correction of hyperglycaemia, but 
should encourage to consider the patient globally and to treat all risk factors present in each individual, 
more particularly weight excess, arterial hypertension and dyslipidaemias (8). 
 Type 2 diabetes is a common disease whose prevalence markedly increases with age (> 10 % 
above 65 years) (9). The objectives of therapy should be clearly defined in each patient in order to adapt 




premise that the benefits of treatment outweigh the risks. As an example, treating a modest 
hyperglycaemia with sulphonylureas or insulin may expose the older patient to severe hypoglycaemia 
that could be more harmful than the initial metabolic disturbance. However, even if primum non nocere 
should be the rule, the antihyperglycaemic treatment of patients with type 2 diabetes should not be 
neglected, especially in younger individuals (40-60 years). Indeed, chronic hyperglycaemia is clearly 
responsible for microangiopathy (retinopathy, nephropathy) and may also favour the development of 
macroangiopathy (coronary heart disease, cerebrovascular diseases, peripheral arteriopathy), in 
combination with other risk factors (7,8). The positive effects of improved glycaemic control on the 
incidence and severity of such complications have been emphasized in the landmark United Kingdom 
Prospective Diabetes Study (UKPDS) in newly diagnosed type 2 diabetic patients followed up to 15 
years  (11,12).   
 
2) Aims of treatment and basic principles 
 
 The goals of treating a patient with type 2 diabetes are twice : first, in the short term, to improve 
the quality of life (less fatigue, reduced polyruria, no urogenital infections) and to avoid acute metabolic 
complications (severe hyperglycaemia leading to hyperosmolar coma or severe iatrogenic 
hypoglycaemic episodes); and second, in the long term, to preserve the patient from both micro- and 
macro-angiopathy complications. Most of the burden of type 2 diabetes results from these long-term 
complications (1). To reach these goals the physician may use non-drug and drug therapies (13,14). 
   The initial treatment of choice in patients with type 2 diabetes is optimization of the meal plan 
and enhancement of physical activity (14). Reduction of excessive body weight should be a main target 
in most patients (6). Unfortunately, traditional dietary strategies, and even very-low-calorie diets, have 
usually not been effective in achieving long-term weight loss. Therefore, several additional strategies 
can be implemented to favour and/or maintain weight loss, such as anti-obesity drugs (orlistat, 
sibutramine) and even, in well-selected extreme cases, bariatric surgery (gastroplasty or gastric bypass) 
(6). The emphasis for medical nutrition therapy in type 2 diabetes should also be placed on achieving 
glucose (50-55% of energy intake as carbohydrates, with limitation of sucrose and advices of 
consuming fibres), lipid (reduction in saturated fat and cholesterol consumption), and blood pressure 
(no more than 3,000 mg/day of sodium) goals (14). An appropriate exercise programme should be an 
adjunct to diet and/or drug therapy to improve glycaemic control, reduce certain cardiovascular risk 




However, attention must be paid to minimizing potential exercise complications and a careful pre-
exercise evaluation should be recommended in all individuals with type 2 diabetes.  
 If progress toward glycaemic goals is not apparent within a 3-month period after initiation of 
diet and exercise therapy, then the use of a pharmacological agent is appropriate (15). Various oral 
antihyperglycaemic agents have been developed during the last 40 years (Table 1) (16,17). Mechanisms 
of action aim at targeting defective insulin secretion (sulphonylureas and more recently meglitinide 
analogues) or defective insulin action (metformin and more recently thiazolidinediones) (Figure 1). 
Alternatively, α-glucosidase inhibitors (acarbose) acts at the intestinal level by slowing the absorption 
of carbohydrates. Insulin can also be used in type 2 diabetes, as initial therapy or most often after 
secondary failure to oral drug treatment. Criteria of drug selection in daily practice should include not 
only patient's clinical characteristics (body weight, degree of hyperglycaemia, age, renal function, ...), 
but also the pharmacological properties of the various compounds available (mode of action, side-
effects, safety profile, and cost) (see below) (5).  Updated recommendations for the management of 
type 2 diabetes have been published by the European NIDDM Policy Group (18). 
 
3) Stepwise pharmacological strategy 
  
 Clinical management of type 2 diabetes mellitus currently employs a stepwise approach, in 
which failure to maintain glycaemic control prompts the introduction of progressively more intensive 
treatment strategies (Figure 2). However, this represents an inherently reactive strategy, with treatment 
decisions following the consequences (i.e. hyperglycaemia) rather than addressing the underlying 
pathology. This approach may explain why treatment of type 2 diabetes is a failure in most cases. Even 
if good glycaemic control remains a key element in the clinical management of type 2 diabetes, 
treatment guidelines will need to be reassessed with the aim of achieving good glycaemic control 
through measures that address the underlying pathogenic mechanisms responsible for type 2 diabetes. 
  
 a) First step  : oral monotherapy 
 After diet failure, patients with type 2 diabetes can be treated with one of the various available 
oral antidiabetic drugs before considering the use of combined therapy or even insulin (Figure 2). It is 
classically recognized that metformin should be preferred in insulin-resistant, hyperinsulinaemic, obese 
patients while sulphonylureas should be prescribed first in non-obese or only modestly overweight, 




effective in non-obese as in obese diabetic subjects. Acarbose appears to be preferable as monotherapy 
in diabetic patients with only modest fasting hyperglycaemia but rather high postprandial glucose 
excursions. In such patients, acarbose can improve glycaemic control without inducing hypoglycaemia. 
The place of the recently developed compounds of the thiazolidinedione family in the general treatment 
strategy of type 2 diabetes still remains to be more precisely specified. Owing to their mode of action, 
pioglitazone and rosiglitazone may be preferred as initial pharmacological therapy after diet failure in 
insulin-resistant patients, as an alternative to metformin, an indication accepted in the United States. 
However, the European Agency for the Evaluation of Medicinal Products (EMEA) has postpone such 
an indication in Europe to reserve the used of these new (more expensive) agents in second line (see 
below). 
 The UKPDS (11,12) showed that sulphonylureas (either chlorpropamide or glibenclamide) and 
metformin initial monotherapy are as effective as insulin in controlling fasting plasma glucose 
concentrations and HbA1c levels during the first ten years after diagnosis and significantly superior to 
diet therapy alone. One advantage of metformin in the obese group with type 2 diabetes was the 
absence of weight gain which contrasted with a significant weight increase in the group treated by 
sulphonylureas or insulin. However, none of these pharmacological approaches was able to avoid a 
progressive deterioration of the metabolic control (assessed by a progressive increase in HbA1c levels) 
that was attributed to an exhaustion of beta cell. A better protection of the beta cell is expected from the 
administration of glitazones although it is not yet proven that such therapy is able to provide a longer 
stabilization of the disease.   
    
 b) Second step : combined oral therapy 
 As the four classes of antidiabetic drugs currently available (sulphonylureas or glinides, 
biguanides, α-glucosidase inhibitors and thiazolidinediones) have different modes and sites of action 
(Figure 1), they may be combined in a stepwise fashion to further improve glycaemic control for most 
patients (Figure 2) (5,15,18). 
  The most common combined therapy associates a sulphonylurea compound that stimulates 
insulin secretion and metformin that facilitates insulin action. Numerous studies have demonstrated that 
both compounds have an at least additive antihyperglycaemic effect, without increasing the side-effects 
of either pharmacological class. Other combinations of oral drugs may also be used. For instance, 
pioglitazone or rosiglitazone may be added after failure of metformin (in obese patients) or 




indications or side-effects) monotherapy. While there is a rationale for a triple therapy (sulphonylurea 
to increase insulin secretion, metformin to reduce hepatic glucose output and glitazone to enhance 
muscular glucose utilisation), no extensive study has yet proven the efficacy and safety of such strategy 
yet. 
  
 c) Third step : insulin therapy 
 Seventy-five years after the discovery of insulin, insulin therapy is still controversial in the 
management of patients with type 2 diabetes so that the questions why, when and how to prescribe 
insulin in those individuals remain without definite answers. The minimum goal of insulin therapy is to 
suppress clinical symptoms of diabetes and the ultimate goal is to prevent long-term complications. 
Insulin therapy may be used as an alternative to oral drugs after diet failure, following secondary failure 
of maximal oral treatment, or when oral agents are contraindicated or become temporarily ineffective. 
While insulin is used rather early in the natural history of the disease in United Kingdom or 
Scandinavian countries, it is used at a much later stage in the south part of Europe, generally after 
secondary failure to oral antidiabetic therapy. Insulin can be administered once daily (long-acting 
insulin, preferably the new insulin glargine), twice daily (a mixture of short- and intermediate acting – 
NPH -  insulins before breakfast and dinner) or sometimes using a basal–bolus scheme (regular insulin 
or fast-acting insulin analogue before each meal and long-acting insulin at bedtime) (19). Besides the 
risk of hypoglycaemia (however much lower than in patients with type 1 diabetes), insulin may trigger 
weight gain in patients wit type 2 diabetes and insulin therapy should always be accompanied by diet 
counseling.   
 In contrast to the use of insulin as only treatment in type 1 diabetes, a disease characterized by a 
pure beta-cell defect, insulin may be combined with various oral antidiabetic drugs in type 2 diabetes, a 
more complex disease combining partially defective insulin secretion and action (Figure 2) (20,21). 
Insulin-sulphonylurea is the combination which has been the most extensively studied. Intermediate 
insulin at bedtime combined with pre-meal sulphonylurea has been shown to be effective in most 
studies, but requires the persistence of significant residual endogenous insulin secretion. Metformin 
may be used in combination with insulin to reduce insulin requirements in obese patients, to improve 
glycaemic control and/or to correct associated metabolic abnormalities. Similar effects of sparing 
insulin dosage and improving metabolic disturbances are expected from the association of insulin 
sensitizers such as glitazones to insulin therapy but some concern has been raised about this 




congestive heart failure (such an indication is not admitted by the EMEA, in contrast to the US Food 
and Drug Administration or FDA). Finally, acarbose may be added to insulin to reduce blood glucose 
variations, especially postprandial early hyperglycaemia and late hypoglycaemia.  
  
4. Therapy risk and benefits 
 As the prevalence of type 2 diabetes and the risk of severe side-effects of oral antidiabetic 
agents are markedly increased with aging, special focus should be put on the specific group of elderly 
diabetic patients (9). In general, the same measures of management are appropriate in the older as in the 
younger patient with diabetes, but may need to be modified in the presence of comorbidities, 
polymedication or social isolation. In particular the risk of severe sulphonylurea-induced 
hypoglycaemia or biguanide-associated lactic acidosis is higher in the elderly, so that those drugs must 
be prescribed with caution in the older population. Meglitinide analogues (repaglinide and nateglinide) 
are more rapidly absorbed and have a shorter half-life than sulphonylureas (16,17). Therefore, they may 
exert a better control of postprandial hyperglycaemia and reduce the risk of  hypoglycaemia at distance 
of the last meal. In addition, they are not excreted by the liver and may be safely used even in case of 
renal insufficiency. Recently launched glitazones (pioglitzone, rosiglitazone) appear to have a good 
safety profile as they do not share the liver toxicity described with troglitazone; however, glitazones, 
which may promote fluid retention, are contra-indicated in patients with congestive heart failure, a 
condition that is more frequently observed in the elderly population. Finally, acarbose can be safely 
used in elderly diabetic patients although  it may induce intestinal side-effects.  
  As for the management of arterial hypertension, the increase of different available drugs will 
probably favour the use of combined therapy, although it remains to be established which combination 
will provide the best results in a given patient with type 2 diabetes (5). In addition, the cost/benefit ratio 
of combined therapy remains to be assessed in large randomised trials, as well as remains to be 
answered the question of whether better metabolic control may be maintained in the long-term with a 
combined therapy as compared with monotherapy. Finally, it is noteworthy that, until now, no long-
term studies in type 2 diabetic patients have shown the superiority of any kind of antihyperglycaemic 
oral agents for postponing or preventing micro-angiopathic complications (11). The UKPDS showed a 
greater reduction in macrovascular complications in the group of overweight diabetic patients treated 
with metformin as compared to the groups treated with diet alone or with intensive therapy including 
sulphonylureas or long-acting insulin (12). Large ongoing studies with pioglitazone or rosiglitazone  




cell protection and more sustained metabolic control, but also may exert a specific cardiovascular 
protection due to pleiotropic effects resulting from improvement of insulin sensitivity (22).  
 Aggressive treatment of other risk factors has been shown to significantly reduce the incidence 
of cardiovascular complications in patients with type 2 diabetes. Treating arterial hypertension with 
either a beta-blocker (atenolol) or an angiotensin-converting enzyme inhibitor (captopril) significantly 
and remarkably  reduced the incidence of diabetic complications in the UKPDS (23). Adequate  
treatment of hypertension has acquired a major importance in the overall management of individuals 
with type 2 diabetes (24). Similarly, aggressive treatment of even modest lipid disturbances should not 
be neglected in diabetic patients. In the subgroup of diabetic patients of the Heart Protection Study (25), 
the subjects who received simvastatin exhibited a significant reduction of cardiovascular morbidity and 
mortality as compared to patients on placebo, even in absence of severe hypercholesterolaemia. 
Therefore, statin administration is now recommended in the management of any patient with type 2 
diabetes at high risk of cardiovascular diseases. Consequently, a maximum benefit would be expected 
from a multifactorial therapy (optimal control of blood glucose, adequate treatment of arterial 
hypertension and dyslipidaemia, prevention of thrombotic state using aspirin). Such a multifactorial 
intervention has been recently shown to reduce by half the incidence of  cardiovascular complications 
in patients with type 2 diabetes (8). 
  
5. Conclusions 
 Type 2 diabetes mellitus is a complex disease whose treatment remains a real challenge. Indeed, 
long-term compliance to life-style modifications is difficult to obtain in diabetic patients and no current 
pharmacological treatment is able to avoid the progression of the disease and the metabolic 
deterioration over years. The possibility that earlier aggressive intervention, potentially involving 
polypharmacy, directed against the pathogenic mechanisms underlying type 2 diabetes, and not just the 
resulting hyperglycaemia, may improve the clinical management of diabetes requires consideration. 
There is at least  a strong rationale for intervention that counter both beta-cell dysfunction and insulin 
resistance. In addition, a multifactorial intervention should be recommended to reduce other 
cardiovascular risk factors such as arterial hypertension and lipid disturbances in order to improve 
cardiovascular prognosis. As the cost of type 2 diabetes appears enormous, essentially due to vascular 
complications, and the treatment has proven numerous limitations yet, prevention of type 2 diabetes 
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Legends to the Figures
 
Figure 1 :  Current status of drug treatment of type 2 diabetes : sites of action of sulphonylureas (or 
glinides), metformin, acarbose, thiazolidinediones (glitazones) and exogenous 
insulin (adapted from reference 16). 
  
Figure 2 :  Stepwise treatment of type 2 diabetes : a guide to selection of oral antidiabetic agents 
from monotherapy to combined therapy, including insulin (adapted from 




Table 1 : Pharmacotherapy for the management of patient with type 2 diabetes and other comorbidities  
 
 1) Glucose-lowering agents 
  Sulphonylureas 
   carbutamide, tolazamide, tolbutamide, chlorpropamide 
   glibenclamide, glipizide, gliclazide, gliquidone, glimepiride 
  Biguanides 
   metformin  
  Thiazolidionediones 
   pioglitazone, rosiglitazone 
  α-glucosidase inhibitors 
   acarbose 
 2) Antihypertensive agents 
  Angiotensin converting enzyme inhibitors or angiotensin AT1 receptor blockers 
  Beta-blockers 
  Diuretics 
  Calcium channel antagonists 
 3) Lipid-lowering agents 
  Statins 




 4) Others 
  Aspirin 
 
 
   
